Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

TVGN

Tevogen Bio Holdings Inc

5.00

Jul 13 • 03:59PM ET -0.06 (-1.19%)

5.00

Aftermarket • 06:18PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Peers: ATNM GRCE INMB LTRN OTLK QNTM RNXT VERU XLO TLPH

| Held by: VTI VTWO VXF VTWG VTWV

Scroll to Statements

Index	RUT
Market Cap	21.10M
Enterprise Value	38.68M
Income	-21.94M
Sales	0.00M
Book/sh	-4.47
Cash/sh	0.16
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	18
IPO	Jan 05, 2022

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	30.58
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.29
Current Ratio	0.29
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-5.84
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -305.12%
Sales past 3/5Y	- -
EPS Y/Y TTM	38.95%
Sales Y/Y TTM	-
EPS Q/Q	50.45%
Sales Q/Q	-
Earnings	Feb 25
EPS/Sales Surpr.	50.66% -

Insider Own	74.41%
Insider Trans	-0.03%
Inst Own	3.24%
Inst Trans	27.55%
ROA	-474.85%
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-33.43%
SMA50	-39.19%
SMA200	-68.22%
Trades

Shs Outstand	4.17M
Shs Float	1.08M
Short Float	6.05%
Short Ratio	2.28
Short Interest	0.07M
52W High	71.00 -92.96%
52W Low	4.14 20.91%
Volatility	8.73% 12.72%
ATR (14)	0.98
RSI (14)	33.03
Beta	0.22
Rel Volume	0.52
Avg Volume	28.70K
Volume	14,823

Perf Week	-14.68%
Perf Month	-52.83%
Perf Quarter	-12.74%
Perf Half Y	-74.36%
Perf YTD	-69.80%
Perf Year	-91.60%
Perf 3Y	-99.08%
Perf 5Y	-
Perf 10Y	-
Recom	3.00
Target Price	100.00
Prev Close	5.06
Price	5.00
Change	-1.19%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-04-26	Downgrade	D. Boral Capital	Buy → Hold
Mar-04-25	Initiated	D. Boral Capital	Buy	$10

Today 10:15PM	Tevogen Bio Announces 2026 Annual Meeting of Stockholders (GlobeNewswire)
Jun-09-26 03:30PM	Tevogen Announces Formation of a Healthcare Services Initiative (GlobeNewswire) -7.65%
May-28-26 12:30PM	Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue (GlobeNewswire) +11.82%
May-21-26 12:15PM	Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization (GlobeNewswire) +10.35%
May-18-26 12:15PM	Letter to Shareholders from CEO Dr. Ryan Saadi (GlobeNewswire) +11.70%
11:45AM	Loading…
May-12-26 11:45AM	Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close (GlobeNewswire)
Apr-27-26 11:50AM	Tevogen.AI Nears Completion of PredicTcell Training; Initiates Commercial Readiness and Debuts Internal Application Portal (GlobeNewswire) -7.28%
Mar-26-26 12:45PM	Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth (GlobeNewswire) -8.11%
Mar-25-26 02:20PM	Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Mar-18-26 12:22PM	Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026) (GlobeNewswire)
Mar-13-26 02:45PM	Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization (GlobeNewswire) -15.67%
12:30PM	Tevogen.AI Reports Advancements in PredicTcell Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure (GlobeNewswire)
Mar-11-26 03:15PM	Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform (GlobeNewswire)
Mar-09-26 07:45AM	Tevogen Names Leadership Team to Execute Diversified Growth Strategy (GlobeNewswire) +6.02%
Mar-06-26 03:40PM	Letter to Shareholders from CEO Dr. Ryan Saadi (GlobeNewswire) -5.74%
12:42PM	Loading…
12:42PM	Tevogen Bio Explores Buyout To Boost Generics Platform (Benzinga)
Mar-05-26 02:50PM	Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical (GlobeNewswire) -16.70%
Mar-04-26 08:00AM	Tevogen Announces Reverse Stock Split (GlobeNewswire) -24.83%
Feb-27-26 02:20PM	Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization (GlobeNewswire) -8.71%
Feb-26-26 04:22PM	UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus (GlobeNewswire)
09:20AM	Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus (GlobeNewswire)
Jan-30-26 03:00PM	Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders (GlobeNewswire)
Jan-29-26 02:45PM	Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue (GlobeNewswire) -5.90%
Jan-12-26 09:00AM	Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025 (GlobeNewswire) -16.45%
Dec-22-25 12:40PM	Tevogen CEO Donates Shares to Support Education for Underprivileged Children (GlobeNewswire)
Dec-19-25 11:10AM	Tevogen CEO Donates Personal Shares to Support Local Fire Department (GlobeNewswire)
Dec-11-25 03:15PM	Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company's Shares of Common Stock (GlobeNewswire)
Dec-09-25 02:20PM	Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine (GlobeNewswire)
Dec-08-25 02:50PM	Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook (GlobeNewswire) +8.81%
Nov-14-25 02:32PM	Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q (GlobeNewswire) -6.12%
03:20PM	Loading…
Nov-05-25 03:20PM	Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID (GlobeNewswire) -5.42%
Nov-03-25 02:45PM	Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn (GlobeNewswire) -6.41%
Oct-29-25 12:35PM	Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress (GlobeNewswire)
Oct-15-25 03:50PM	Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest (GlobeNewswire) +7.32%
Sep-25-25 08:30AM	Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell-Based Therapies with 100x PredicTcell Beta Data Expansion (GlobeNewswire)
Sep-24-25 08:35AM	Tevogen highlights potential role of TVGN 489 on impact of Long COVID (TipRanks)
Sep-23-25 08:30AM	Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID (GlobeNewswire)
Sep-19-25 03:40PM	Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans (GlobeNewswire) -7.68%
Sep-10-25 11:59AM	Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston (GlobeNewswire)
Sep-09-25 03:15PM	Tevogen Estimates 5-Year Top-Line Revenue of ~$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection (GlobeNewswire)
Sep-08-25 09:27AM	Tevogen Values TVGN-489 at $9-$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell Allogeneic T Cell Platform (GlobeNewswire)
Sep-04-25 03:48PM	Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas (GlobeNewswire)
Sep-03-25 04:15PM	Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2 (GlobeNewswire)
Aug-27-25 03:20PM	Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure (GlobeNewswire)
Aug-26-25 02:50PM	Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity (GlobeNewswire)
Aug-25-25 03:10PM	Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions (GlobeNewswire)
Aug-22-25 03:25PM	Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma (GlobeNewswire)
Aug-19-25 03:40PM	REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts (GlobeNewswire)
12:10PM	Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum (GlobeNewswire)
Aug-18-25 05:50PM	Tevogen CEO Donates Personal Shares to Support Local Law Enforcement (GlobeNewswire)
05:15PM	Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery (GlobeNewswire)
Aug-14-25 03:55PM	Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected (GlobeNewswire)
Aug-13-25 03:53PM	Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell Model With a Focus on Oncology (GlobeNewswire)
Aug-12-25 11:09AM	Healthcare AI Market Explodes 38.5% Annually as Diagnostics Gain FDA Traction (PR Newswire)
Aug-11-25 03:45PM	Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion (GlobeNewswire) +8.83%
01:24PM	REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion (GlobeNewswire)
11:58AM	Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow (GlobeNewswire)
09:28AM	REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders (GlobeNewswire)
Aug-08-25 11:37AM	REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions (GlobeNewswire)
Aug-07-25 09:00AM	Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy (GlobeNewswire) -8.75%
Aug-06-25 03:59PM	Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions (GlobeNewswire)
Aug-05-25 02:32PM	Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell Model With a Focus on Oncology (GlobeNewswire)
Aug-01-25 03:57PM	Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders (GlobeNewswire)
03:30PM	Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion (GlobeNewswire)
Jul-30-25 12:41PM	Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision (GlobeNewswire)
Jul-28-25 11:52AM	Tevogen.AI Applauds U.S. Government's AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare (GlobeNewswire)
Jul-18-25 12:36PM	Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides (GlobeNewswire)
Jul-17-25 09:15AM	Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility (GlobeNewswire)
Jul-16-25 06:35PM	From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine (PR Newswire)
11:57AM	Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell Alpha Launch (GlobeNewswire)
Jul-14-25 09:30AM	Tevogen.AI Builds Alpha Version of PredicTcell Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs (GlobeNewswire) +5.88%
Jul-10-25 03:13PM	Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation (GlobeNewswire)
Jun-30-25 02:28PM	Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters (GlobeNewswire)
09:50AM	AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway (PR Newswire)
Jun-18-25 08:30AM	Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery (GlobeNewswire)
Jun-10-25 09:15AM	Tevogen expands headquarters in Warren, New Jersey (TipRanks) +12.73%
Jun-09-25 09:00AM	Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives (GlobeNewswire) -23.08%
May-30-25 11:01AM	Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships (GlobeNewswire)
May-25-25 06:19PM	Tevogen Peports Plans to Increase the Target Population for TVGN 489 (Insider Monkey)
May-23-25 03:49PM	Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow (GlobeNewswire) +6.50%
May-22-25 01:21PM	Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting (GlobeNewswire)
May-12-25 08:00AM	Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation (GlobeNewswire) +9.17%
May-05-25 12:35PM	AI Healthcare Boom Gains Speed as Regulators and Innovators Align (PR Newswire)
May-02-25 03:45PM	Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest (GlobeNewswire)
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -5.01%
Apr-30-25 03:49PM	CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment (GlobeNewswire)
Apr-29-25 04:50PM	Tevogen sees launch year oncology business revenue $1B (TipRanks) +7.74%
01:48PM	Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts (GlobeNewswire)
08:00AM	Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald (GlobeNewswire)
Apr-28-25 04:36PM	Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion (GlobeNewswire) -5.52%
Apr-25-25 02:33PM	Tevogen Bio Announces 2025 Annual Meeting (GlobeNewswire)
Apr-17-25 02:54PM	Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility (GlobeNewswire)
Apr-16-25 08:58AM	WHO and WEF Are Pushing AI in Global Healthcare -- What It Means for the Market (PR Newswire)
Apr-15-25 02:03PM	Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction (GlobeNewswire)
Apr-14-25 01:53PM	Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald (GlobeNewswire)
Apr-11-25 04:00PM	Tevogen Bio Holdings: Initiating Sell Rating Based On Pipeline Uncertainty And Cash Constraints (Seeking Alpha) +8.00%
Apr-09-25 02:45PM	Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump's Initiative to Encourage Pharmaceutical Manufacturing in United States (GlobeNewswire) +16.67%
Apr-08-25 05:53PM	Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI Biotechs (GlobeNewswire) -6.80%
Apr-07-25 03:58PM	Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company's Mission (GlobeNewswire)
Mar-26-25 03:12PM	Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast (GlobeNewswire)

Tevogen Bio Holdings, Inc. is a clinical-stage specialty immunotherapy company, which engages in the provision of off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. It focuses on its product, ExacTcell, a technology that treats acute viral infections, long-term consequences of viral infections, and viral and non-viral induced cancers. The company was founded in April 2021 and is headquartered in Warren, NJ.

M.P.H.Dr. Ryan H. Saadi M.D.

Chief Financial OfficerMr. Kirti Desai CPA

Chief Scientific Officer and Global R&D LeadDr. Neal Flomenberg M.D.

Chief Technical OfficerMr. Stephen Chen M.B.A.

Chief Information Officer & Head of Tevogen.aiMr. Mittul Mehta

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Flomenberg Neal	See Remarks	Mar 11 '26	Sale	7.26	452	3,282	77,441	Mar 17 04:29 PM
Flomenberg Neal	See Remarks	Mar 13 '26	Sale	6.40	501	3,206	76,940	Mar 17 04:29 PM
Flomenberg Neal	See Remarks	Mar 10 '26	Sale	7.75	19	147	77,893	Mar 17 04:29 PM
Desai Kirti	Officer	Feb 06 '26	Proposed Sale	0.31	330,000	103,224		Feb 06 03:09 PM
Desai Kirti	Officer	Dec 30 '25	Proposed Sale	0.40	15,500	6,149		Dec 30 10:12 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TVGN

Tevogen Bio Holdings Inc

Upgrade your Finviz experience